Money Map Passport Club

Dear Reader, As we head into this holiday week for Americans, the markets have the jitters for a couple of reasons. First, the Congressional Super Committee is expected to announce that they've been unable to reach a deal to slash the U.S.

Email - 45 Dear Reader, As we stare down the muzzle of a debt-ceiling gun, there are three moves I am recommending on the options side. This crisis will be overcome, if only in a partly satisfactory way, within the next week. But the

Email - 54 Dear Reader, Wednesday's volatile trading gave our VXX September 2011 $28 call (VXX110917C28) options a real boost - and I don't want to see it slip away. Here's what to do as soon possible: Sell your remaining VXX September

Email - 288 Dear Reader, We are heading into truly uncharted territory. What's happening in Washington is appalling, disgusting, and disgraceful on so many levels; it effectively holds our money "hostage" until things settle down. That's

Dear Reader, From time to time, our research uncovers special opportunities worth acting on immediately. Like back in January, when we recommended shares of Depomed Inc. (NasdaqGS:DEPO) in advance of an important FDA approval. Within days, the

Dear Reader, If I were to give you three guesses as to where my trading colleagues and I spent our time on this morning's 0-dark thirty call, the first two wouldn't count. So let's just jump right in. Here's what's on my radar: The markets

Action to take: Place a trailing stop at $7.81 to lock in profits on Depomed Inc. (NasdaqGS:DEPO). Dear Reader, Let me begin - once again - with a warm welcome. When you joined the Money Map Passport Club, you joined a very select group of

Dear Reader, Never let it be said that Money Map Passport Club Members are behind the curve! Not only did we identify Depomed Inc. (NasdaqGM:DEPO) well in advance of its most recent pop, but we did so on the merits of the company, its

An Explosive New Stock Recommendation For Passport Club Members Only Dear Reader, We just released an urgent Passport Club recommendation. As a member, you have exclusive access to it. Here’s the full report. This small-cap biotech is

Dear Reader, We've just put the finishing touches on your latest Passport Club report. In this quarter's outlook, Chief Investment Strategist Keith Fitz-Gerald covers everything from unconventional investments to the fragmented markets, and

Dear Reader, We've just put the finishing touches on your latest Passport Club report. In this mid-quarter outlook, Chief Investment Strategist Keith Fitz-Gerald covers everything from gold and the U.S. dollar to emerging markets, the